These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16705566)

  • 1. Rhabdomyolysis during therapy with daptomycin.
    Papadopoulos S; Ball AM; Liewer SE; Martin CA; Winstead PS; Murphy BS
    Clin Infect Dis; 2006 Jun; 42(12):e108-10. PubMed ID: 16705566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
    Mohr JF; Friedrich LV; Yankelev S; Lamp KC
    Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.
    Kullar R; Davis SL; Levine DP; Zhao JJ; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ
    Pharmacotherapy; 2011 Jun; 31(6):527-36. PubMed ID: 21923436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
    Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
    Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin.
    Kazory A; Dibadj K; Weiner ID
    J Antimicrob Chemother; 2006 Mar; 57(3):578-9. PubMed ID: 16410267
    [No Abstract]   [Full Text] [Related]  

  • 7. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.
    Lewis JS; Owens A; Cadena J; Sabol K; Patterson JE; Jorgensen JH
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1664-5. PubMed ID: 15793168
    [No Abstract]   [Full Text] [Related]  

  • 8. Daptomycin.
    Prescrire Int; 2007 Dec; 16(92):245. PubMed ID: 18095389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daptomycin for the treatment of vancomycin-resistant enterococcal infections.
    Grim SA; Hong I; Freeman J; Edwards C; Clark NM
    J Antimicrob Chemother; 2009 Feb; 63(2):414-6. PubMed ID: 19015143
    [No Abstract]   [Full Text] [Related]  

  • 10. Administration interval and daptomycin toxicity: a case report of rhabdomyolysis.
    Sbrana F; Di Paolo A; Pasanisi EM; Tagliaferri E; Arvia C; Puntoni M; Leonildi A; Bigazzi F; Danesi R; Rovai D; Tascini C; Menichetti F
    J Chemother; 2010 Dec; 22(6):434-5. PubMed ID: 21303756
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety of daptomycin in patients receiving hemodialysis.
    Mueller BA; Crompton JA; Donovan BJ; Yankalev S; Lamp KC
    Pharmacotherapy; 2011 Jul; 31(7):665-72. PubMed ID: 21923453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin in the treatment of bacteremia.
    Sakoulas G; Golan Y; Lamp KC; Friedrich LV; Russo R
    Am J Med; 2007 Oct; 120(10 Suppl 1):S21-7. PubMed ID: 17904947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of plasma and peritoneal fluid concentrations of daptomycin in a patient with Enterococcus faecium peritonitis.
    Burklein D; Heyn J; Kirchhoff C; Ozimek A; Traunmuller F; Joukhadar C; Rothenburger M; Mutschler W; Heindl B
    Int J Antimicrob Agents; 2008 Oct; 32(4):369-71. PubMed ID: 18701260
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.
    Figueroa DA; Mangini E; Amodio-Groton M; Vardianos B; Melchert A; Fana C; Wehbeh W; Urban CM; Segal-Maurer S
    Clin Infect Dis; 2009 Jul; 49(2):177-80. PubMed ID: 19500039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New drugs; daptomycin].
    van Bronswijk H; Dubois EA; van Dissel JT; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(50):2777-8. PubMed ID: 18232197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.
    Bhavnani SM; Rubino CM; Ambrose PG; Drusano GL
    Clin Infect Dis; 2010 Jun; 50(12):1568-74. PubMed ID: 20462352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients.
    Gallagher JC; Perez ME; Marino EA; LoCastro LG; Abrardo LA; MacDougall C
    Pharmacotherapy; 2009 Jul; 29(7):792-9. PubMed ID: 19558253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A balancing act: microbe versus muscle.
    Cosgrove SE; Corey GR
    Clin Infect Dis; 2009 Jul; 49(2):181-3. PubMed ID: 19500038
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections.
    Corona Pérez-Cardona PS; Barro Ojeda V; Rodriguez Pardo D; Pigrau Serrallach C; Guerra Farfán E; Amat Mateu C; Flores Sanchez X
    J Antimicrob Chemother; 2012 Jul; 67(7):1749-54. PubMed ID: 22511636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daptomycin, a lipopeptide antibiotic in clinical practice.
    Weis F; Beiras-Fernandez A; Schelling G
    Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.